Inhibition effect of glycyrrhizin in lipopolysaccharide-induced high-mobility group box 1 releasing and expression from RAW264.7 cells

Shock

Volumn 43, Issue 4, 2015, Pages 412-421

  Wu, Chuan Xin ^a   He, Lin Xiang ^a   Guo, Hui ^a   Tian, Xiao Xing ^a   Liu, Qi ^a   Sun, Hang ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Glycyrrhizin; High mobility group box 1 protein; Lipopolysaccharide; Sepsis

Indexed keywords

GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; HMGB1 PROTEIN, MOUSE;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL NUCLEUS; CONFOCAL LASER MICROSCOPY; CYTOPLASM; DNA BINDING; ENZYME PHOSPHORYLATION; FLUORESCENCE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; IMMUNOCYTOCHEMISTRY; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; SEPSIS; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHEMISTRY; FLUORESCENCE MICROSCOPY; INFLAMMATION; METABOLISM; MOUSE; RAW 264.7 CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL NUCLEUS; CYTOPLASM; GLYCYRRHIZIC ACID; HMGB1 PROTEIN; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICROSCOPY, FLUORESCENCE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RAW 264.7 CELLS; SEPSIS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924916409     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000309     Document Type: Article

References (29)

1. Dellinger RP, Levy MM, Carlet JM, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296-327, 2008.
2. Van der Poll T, Opal SM: Host-pathogen interactions in sepsis. Lancet Infect Dis 8(1):32-43, 2008.
3. Opal SM: The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int J Med Microbiol 297(5):365-377, 2007.
4. Cinel I, Opal SM: Molecular biology of inflammation and sepsis: a primer. Crit Care Med 37(1):291-304, 2009.
5. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ: HMGB1 as a DNA-binding cytokine. J Leukoc Biol 72(6):1084-1091, 2002.
6. Yang H, Tracey KJ: Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799(1-2):149-156, 2010.
7. Mollica L, De Marchis F, Spitaleri A, Dalla Costa C, Pennacchini D, Zamai M, Agresti A, Trisciuoglio L, Musco G, Bianchi ME: Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 14(4):431-441, 2007.
8. Ogiku M, Kono H, Hara M, Tsuchiya M, Fujii H: Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J Pharmacol Exp Ther 339(1):93-98, 2011.
9. Kim SW, Jin Y, Shin JH, Kim ID, Lee HK, Park S, Han PL, Lee JK: Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol Dis 46(1):147-156, 2012.
10. Smolarczyk R, Cichoc T, Matuszczak S, Mitrus I, Lesiak M, Kobusińska M, Kamysz W, Jarosz M, Sieroń A, Szala S: The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Arch Immunol Ther Exp (Warsz) 60(5):391-399, 2012.
11. Wang W, Zhao F, Fang Y, Li X, Shen L, Cao T, Zhu H: Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response. Crit Care 17(2):R44, 2013.
12. Li W, Li J, Sama AE, Wang H: Carbenoxolone blocks endotoxin-induced PKR activation and HMGB1 release. Mol Med 19:203-211, 2013.
13. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285(5452):248-251, 1999.
14. Wang H, Ward MF, Sama AE: Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32(4):348-357, 2009.
15. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson- Harris H, Janson A, Kokkola R, Zhang M, Yang H, et al.: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192(4):565-570, 2000.
16. Degryse B, Bonaldi T, Scaffidi P, Müller S, Resnati M, Sanvito F, Arrigoni G, Bianchi ME: The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 152(6):1197-1206, 2001.
17. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A: The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3(10):995-1001, 2002.
18. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ: HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 164(10 Pt 1): 1768-1773, 2001.
19. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E: Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279(9):7370-7377, 2004.
20. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61(1):1-9, 2005.
21. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME: Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22(20):5551-5560, 2003.
22. Wu CX, Sun H, Liu Q, Guo H, Gong JP: LPS induces HMGB1 relocation and release by activating the NF-κB-CBP signal transduction pathway in the murine macrophage-like cell line RAW264.7. J Surg Res 175(1):88-100, 2012.
23. Hernandez1 JM, Floyd DH, Weilbaecher KN, Green PL, Boris-Lawrie K: Multiple facets of JunD gene expression are atypical among AP-1 family members. Oncogene 27(35):4757-4767, 2008.
24. Yoh T, Nakashima T, Sumida Y, Kakisaka Y, Nakajima Y, Ishikawa H, Sakamoto Y, Okanoue T, Mitsuyoshi H: Effects of glycyrrhizin on glucocorticoid signaling pathway in hepatocytes. Dig Dis Sci 47(8):1775-1781, 2002.
25. Takei H, Baba Y, Hisatsune A, Katsuki H, Miyata T, Yokomizo K, Isohama Y: Glycyrrhizin inhibits interleukin-8 production and nuclear factor-κB activity in lung epithelial cells, but not through glucocorticoid receptors. J Pharmacol Sci 106(3):460-468, 2008.
26. Casey LC: Immunologic response to infection and its role in septic shock. Crit Care Clin 16(2):193-213, 2000.
27. Beutler BA, Milsark IW, Cerami A: Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 135(6):3972-3977, 1985.
28. Karin M, Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749-759, 2005.
29. Saitoh S, Akashi S, Yamada T, Tanimura N, Kobayashi M, Konno K, Matsumoto F, Fukase K, Kusumoto S, Nagai Y, et al.: Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol 16(7): 961-969, 2004.